In a bid to tackle the obesity epidemic affecting 42% of Americans, the Biden administration has proposed expanding Medicare and Medicaid coverage for anti-obesity medications. This would potentially benefit an estimated 3.4 million Medicare and 4 million Medicaid enrollees. The initiative comes as part of a broader agenda to lower healthcare costs. The proposal's fate remains uncertain under the incoming Trump administration, particularly with potential opposition from his appointed health officials. Advocates believe the expansion could save costs in the long term, while critics question its implications for drug pricing.